Melanoma differentiation associated gene-7 (mda-7) was cloned using subtraction hybridization from terminally differentiated human melanoma cells. Based on structural and functional properties, mda-7 is now recognized as interleukin-24 (IL-24), a new member of the expanding IL-10 gene family. Unique properties of mda-7/IL-24 include its ability to selectively induce growth suppression, apoptosis and radiosensitization in diverse human cancer cells, without causing similar effects in normal cells. The utility of mda-7/IL-24, administered by means of a replication-incompetent adenovirus, as a gene therapy for cancer has recently received validation in patients, highlighting an important phenomenon initially observed in pancreatic tumor cells, namely a 'potent bystander apoptosis-inducing effect' in adjacent tumor cells not initially receiving this gene product. We presently investigated the contribution of mda-7/IL-24 secreted by normal cells in mediating this 'bystander effect', and document that normal cells induced to produce mda-7/ IL-24 following infection with recombinant adenoviruses expressing this cytokine secrete mda-7/IL-24, which modifies the anchorage-independent growth, invasiveness, survival and sensitivity to radiation of cancer cells that contain functional IL-20/IL-22 receptors, but not in cancer cells that lack a complete set of receptors. Moreover, the combination of secreted mda-7/IL-24 and radiation engenders a 'bystander antitumor effect' not only in inherently mda-7/IL-24 or radiation-sensitive cancer cells, but also in tumor cells overexpressing the antiapoptotic proteins bcl-2 or bcl-x L and displaying resistance to either treatment alone. The present studies provide definitive evidence that secreted mda-7/IL-24 from normal cells can induce direct antitumor and radiation-enhancing effects that are dependent on the presence of canonical receptors for this cytokine on tumor cells. Moreover, we now describe a novel means of enhancing mda-7/IL-24's therapeutic potential by targeting normal cells to produce and release this cancer-specific apoptosis-inducing cytokine, a strategy that could be employed as an innovative way of using this unique gene product for treating metastatic disease.
Introduction
Cancer gene therapies that re-introduce tumor suppressor/apoptosis-inducing genetic elements, such as wildtype p53 or the retinoblastoma (RB) gene, into tumor cells by means of viruses or other approaches have yielded marginal success as single-modality cancer therapeutics ). An inherent limitation of this approach is the inability to administer the appropriate gene to a majority of the tumor mass (Frank et al., 1998; Fisher et al., 2003; Lebedeva et al., 2003b Lebedeva et al., , 2005a Sauane et al., 2003b) . In this context, a suppressor/apoptosis-inducing gene that displays a significant primary antitumor effect, as well as a potent 'bystander antitumor effect', should provide a means of obviating this impasse of poor tumor delivery. A gene discovered in our laboratory using subtraction hybridization (Jiang and Fisher, 1993; Jiang et al., 1995) that embodies these traits and is now displaying significant potential as a cancer-gene therapeutic is mda-7/IL-24 Fisher et al., 2003; Sauane et al., 2003b; Cunningham et al., 2005; Lebedeva et al., 2005a; Tong et al., 2005) . In human tumor xenograft models (Su et al., 1998 Madireddi et al., 2000; Saeki et al., 2002; Nishikawa et al., 2004) and recently in a Phase I clinical trial in patients with advanced carcinomas and melanomas, intratumoral injection of Ad.mda-7 produced objective clinical responses and direct antitumor apoptosis-inducing effects, as well as a potent 'bystander apoptotic effect' in tumor cells not initially injected with Ad.mda-7 Saeki et al., 2002; Fisher et al., 2003; Cunningham et al., 2005; Lebedeva et al., 2005a; Tong et al., 2005) . These remarkable attributes of mda-7/IL-24 suggest substantial potential as a gene therapy for diverse cancers.
Mda-7 was initially cloned using a genetic screen to identify and define genes controlling cancer cell growth and differentiation in human melanoma cells (Jiang and Fisher, 1993; Jiang et al., 1995) . Based on its structure (containing an IL-10 signature motif), chromosomal location (1q32) and secretion by cells, mda-7 is now classified as part of the expanding IL-10 gene family and has been given the name IL-24 (Blumberg et al., 2001; Huang et al., 2001; Caudell et al., 2002; Pestka et al., 2003 Pestka et al., , 2004 Gopalkrishnan et al., 2004; Lebedeva et al., 2005a) . When present at perceived physiological levels, mda-7/IL-24, which is expressed in defined tissues of the immune system (Huang et al., 2001) , has immunostimulatory functions (Caudell et al., 2002; Fisher et al., 2003; Tong et al., 2005) , although its precise role in modulating immune responses requires clarification. Initial studies document that mda-7/IL-24 induces growth suppression and a reduction in colony formation in a wide-spectrum of human cancers, without affecting normal cells (Jiang et al., 1995 (Jiang et al., , 1996 . Experiments expanding on these observations using a replicationincompetent adenovirus to administer mda-7/IL-24, Ad.mda-7, confirm growth suppression and apoptosis selectively in cancer cells, without harming normal cells (Su et al., 1998 Saeki et al., 2000 Saeki et al., , 2002 Mhashilkar et al., 2001; Lebedeva et al., 2002 Lebedeva et al., , 2003a Lebedeva et al., , c, 2005a Sarkar et al., 2002; Sauane et al., 2003a Sauane et al., , 2004b Yacoub et al., 2003a Yacoub et al., , b, c, 2004 ). Extensions of cell culture studies into human tumor xenograft mouse models confirm that Ad.mda-7 has cancer-growthsuppressing and tumor apoptosis-inducing properties in vivo (Su et al., 1998 Madireddi et al., 2000; Saeki et al., 2002; Yacoub et al., 2003c) . Additional attributes of mda-7/IL-24, which complement its utility as a gene therapy for cancer include its ability to radiosensitize tumor cells Su et al., 2003a; Yacoub et al., 2003b Yacoub et al., , c, 2004 Nishikawa et al., 2004) and inhibit tumor angiogenesis (Saeki et al., 2002; Fisher et al., 2003; Ramesh et al., 2003; Nishikawa et al., 2004) .
We have now investigated a specific and previously unexplored aspect of the 'antitumor bystander effect' of mda-7/IL-24 involving release of MDA-7/IL-24 protein by normal cells and document that secretion of MDA-7/ IL-24 protein from normal cells results in an inhibition of anchorage-independent growth and tumor cell invasion, a decrease in cell survival, an induction of tumor cell apoptosis and an enhancement in the sensitivity of tumor cells to radiation. These effects are contingent upon tumor cells having a complete set of functional receptors for mda-7/IL-24, since non-small-cell lung carcinoma cells (A549) that lack IL-20/IL-22 receptor components are resistant to secreted MDA-7/IL-24's antiproliferative and radiation-enhancement effects. These findings complement a recent study investigating the effects of secreted glycosylated, tumor-cell-generated MDA-7/IL-24 protein (produced by a stable 293 cell clone expressing a transfected mda-7/IL-24 gene), which causes a dose-dependent induction of programmed cell death in human melanoma cells . Moreover, this apoptosis-inducing effect of secreted glycosylated, tumor-derived MDA-7/IL-24 in melanoma cells was also dependent on the presence of IL-20/IL-22 receptors. We presently show that exposure of prostate cancer cells that are resistant to both radiation and Ad.mda-7, resulting from overexpression of the bcl-2 family member antiapoptotic proteins Bcl-2 or Bcl-x L , to mda-7/IL-24 secreted by normal early-passage and immortalized cells still promotes radiosensitization. These studies provide an explanation for specific antitumor effects observed when administering mda-7/IL-24 to cell populations containing both normal and tumor cells. Moreover, this profound 'antitumor bystander effect' suggests that mda-7/IL-24 will prove useful in treating not only primary tumors but also metastases, and the therapeutic benefits of mda-7/IL-24 will be enhanced by combination treatment with radiation.
Results

Infection of immortalized normal human cells with
Ad.mda-7 results in secreted mda-7/IL-24 that suppresses anchorage-independent growth of DU-145 human prostate carcinoma cells Infection of primary and immortalized normal human melanocytes, astrocytes or prostate epithelial cells with Ad.mda-7 results in intracellular and secreted MDA-7/ IL-24 protein without provoking cell death or significant growth suppression in these normal cells Su et al., 2003a) . Since these previous studies were performed independently, no prior information is available directly quantitating the amount of intracellular and secreted protein present after infection of these different normal cells with Ad.mda-7. Based on this consideration, FM516-SV (SV40-immortalized normal early passage melanocytes), P69 (SV40-immortalized normal early passage prostate epithelial cells) and primary human fetal astrocyte (PHFA)-IM (hTERT-immortalized PHFAs) cells were infected with 20, 50 or 100 pfu/cell of Ad.mda-7, and the levels of intracellular and secreted mda-7/IL-24 protein were determined by Western blotting 48 h later ( Figure 1a ). The levels of both intracellular and secreted MDA-7/IL-24 proteins were dramatically higher in PHFA-IM cells than in P69 or FM516-SV cells. Intracellular levels of MDA-7/IL-24 proteins were similar in FM516-SV or P69 cells, whereas the levels of secreted MDA-7/IL-24 proteins were greater in FM516-SV than P69 cells (Figure 1a) . The reason for this differential MDA-7/IL-24 synthesis and secretion following infection with Ad.mda-7 is not presently known. It could reflect clonal variability or inherent differences in the capacity of these histologically distinct cell types to produce, process and/or secrete MDA-7/IL-24 protein.
To determine if secreted mda-7/IL-24 proteins display biological activity toward uninfected cancer cells, we employed agar-diffusion anchorage-independent growth assays (Sauane et al., 2004b; Yacoub et al., 2004) . For these experiments, normal cells were plated in tissue culture plates; 24 h later, they were infected with 100 pfu/cell of Ad.vec, Ad.mda-7 or Ad.mda-7-SP À (an adenovirus which expresses mda-7/IL-24 without a signal peptide, resulting in only intracellular and no secreted MDA-7/IL-24 protein) (Sauane et al., 2004b) , washed extensively (5 Â with PBS) and then overlaid with 0.4% agar/medium containing 1 Â 10 5 target cells (in the experiment shown, DU-145 cells) (Figure 1b ). Cultures were refed with 0.4% agar/medium every three to four days and colonies X2 mm were determined in triplicate plates after 2 weeks growth. Infection of FM516-SV, PHFA-IM or P69 cells with Ad.mda-7, but not Ad.mda-7-SP À , which does not result in secreted MDA-7/IL-24 protein (Sauane et al., 2004b ) (data not shown), resulted in a comparable inhibition in anchorage-independent growth of DU-145 cells seeded in the agar overlay (Figure 1b) . In addition, the sizes of the DU-145 agar colonies were on average smaller in normal cultures infected with Ad.mda-7 versus normal cells infected with Ad.vec or Ad.mda-7SP
À (data not shown). Based on the different levels of MDA-7/IL-24 protein secreted by these normal immortal cells following infection with Ad.mda-7, a minimal biologically active threshold level of mda-7/IL-24 protein may be released by all of the normal cells, resulting in an analogous inhibitory effect on the growth of DU-145 cancer cells in agar. This could occur by continued cytokine secretion during the assay by infected normal cells culminating in a threshold level of MDA-7/IL-24 required to evoke an inhibitory response in cancer cells.
Secretion of MDA-7/IL-24 by both cancer and immortalized normal human cells infected with Ad.mda-7 suppresses growth and induces apoptosis in human cervical carcinoma, HeLa, cells
To investigate further the 'antitumor bystander effect' of secreted MDA-7/IL-24 protein, we performed a series of cocultivation experiments in which infected cancer or normal immortalized human cells were mixed with noninfected HeLa cancer cells and induction of apoptosis in the noninfected HeLa cells was quantified using flow cytometry. To facilitate this assay, we generated a HeLa cell clone that stably expresses green fluorescence protein (GFP), thereby permitting us to distinguish these cells from non-GFP-expressing cells infected with Ad.mda-7. Preliminary studies confirmed that HeLa-GFP cells displayed similar sensitivity to Ad.mda-7-induced growth inhibition and apoptosis induction, as monitored by MTT and Annexin V staining assays, as did HeLa-hygromycin-resistant or unmodified parental HeLa cells (data not shown).
To characterize the 'antitumor bystander effect' of secreted MDA-7/IL-24, different cancer and immortalized normal cells were infected with 100 pfu/cell of Ad.vec, Ad.mda-7 or Ad.mda-7 SP À viruses, and the next day they were mixed in different ratios with noninfected HeLa-GFP cells. Cocultivated cells were incubated for 30, 48 or 72 h, collected and stained with allophycocyanin (APC)-labeled Annexin V. During flow cytometry analysis, GFP-positive cells were gated and Annexin V binding was quantitated only in gated cells. In parallel experiments, apoptosis levels were assessed in noncocultivated Ad.mda-7-infected cells. As shown in Figure 2 , secretion of MDA-7/IL-24 protein from human cancer and 100 pfu/cell of Ad.mda-7 were detected by Western blot analysis using rabbit anti-mda-7/IL-24 antibody. For evaluation of loading controls, the same membrane was reprobed with mouse anti-EF1a antibody. (b) Normal immortalized human cells were seeded in 6-cm tissue culture plates and, 24 h later, were infected with 100 pfu/cell of Ad.vec, Ad.mda-7 or Ad.mda-7SP À . At 6-8 h after infection, cells were washed extensively (5 Â with PBS) and then overlaid with 0.4% agar/medium containing 1 Â 10 5 target cells . Cells were refed with 0.4% agar/medium every 3-4 days, and colonies X2 mm were determined after 2 weeks growth. Results are average of three plates7s.d. from the mean, *Po0.01
MDA-7/IL-24 bystander antitumor activity Z Su et al cells, DU-145, PC-3, HeLa (top panels), and normal immortalized human cells, P69, PHFA-IM, FM516-SV (bottom panels), mediated apoptosis in noninfected GFP-labeled HeLa cells. As expected, the degree of apoptosis induced by the secreted proteins in noninfected cells depended on the initial ratio of infected to noninfected cells at the time of cocultivation, which determines the amount of secreted proteins present, and on the longevity of the infected cells, which serve as a reservoir and continuous source of MDA-7/IL-24 proteins. Of note, the onset of apoptosis in HeLa-GFP cells mixed with Ad.mda-7-infected PC-3 cells occurs later than in HeLa-GFP cells mixed with Ad.mda-7-infected DU-145 or HeLa cells. This finding can be explained by the observation that infection of PC-3 cells with Ad.mda-7 results in a more delayed and protracted production of intracellular and secreted MDA-7/IL-24 protein as compared to DU-145 or HeLa cells (Huang et al., 2001; Lebedeva et al., 2003a) . In most cases involving infected cancer cells, except PC-3, apoptosis reached a maximum at 48 h and then declined because infected cells were apoptotic and were no longer available to synthesize and secrete MDA-7/ IL-24 protein. In the case of PC-3 cells, apoptosis increased up to 72 h of incubation, since it took a longer incubation period to kill these cells following Ad.mda-7 infection; therefore, they were able to produce MDA-7/ IL-24 protein for a more extended period before they died . This prolonged apoptosisinducing effect was even more pronounced in the case of infected immortalized normal cells (FM516-SV, P69 and PHFA-IM) ( Figure 2 ). Upon Ad.mda-7 infection, these cells started to produce and secrete protein as early as 24 h post-infection ( Figure 1a ) Su et al., 2003a) . Since there is no deleterious effect of mda-7/IL-24 in these cells, continuous production of protein accounts for prolonged apoptosis induction in noninfected HeLa cells. Based on the amount of MDA-7/IL-24 protein secreted (Figure 1a ), apoptosis could be detected earlier and the degree of apoptosis induction was higher when HeLa-GFP cells were mixed with infected PHFA-IM cells, than with FM516-SV or P69 cells. As envisaged, infection of both immortalized normal cells and cancer cells with Ad.vec and Ad.mda-7-SP À viruses and subsequent mixing with HeLa-GFP cells did not promote apoptosis. In both scenarios, treatment with these viruses did not result in secreted MDA-7/IL-24 protein ( Figure 1a ) and, accordingly, no 'antitumor bystander apoptotic effect' in noninfected HeLa-GFP cells. In this context, stable expression of mda-7/IL-24 in normal cells provides an innovative method of insuring high and continuous levels of production and secretion of MDA-7/IL-24 protein in the circulation and tumor microenvironment. This approach represents an inventive therapeutic paradigm in the context of specific tumor microenvironments, such as the brain or liver, and systemically as a unique means of promoting prophylaxis and therapy against metastases. Additionally, by genetically modifying appropriate cell types that can circulate and target cancer cells, such as dendritic cells and tissue-and celltype-specific stem cell populations, to produce and secrete mda-7/IL-24, it would conceivably be possible to directly target primary and disseminated tumor cells for destruction by induction of apoptosis.
MDA-7/IL-24 secretion by normal cells inhibits invasion of DU-145 and BxPC-3, but not A549, cells
Infection of human melanoma (Sauane et al., 2004b) or non-small-cell lung carcinoma cells with Ad.mda-7 inhibits invasion. To determine if cocultivation of normal cells infected with Ad.mda-7 and secreting MDA-7/IL-24 protein exerts a similar effect on tumor cell invasion into Matrigel, P69 cells were uninfected or infected with 100 pfu/cell of Ad.mda-7, cocultivated with various tumor cells for 48 h and then evaluated for invasion (Figure 3a and b). Under these experimental conditions, no decrease in cell growth or viability was evident and no apoptosis was induced in these cancer cells (unpublished data). However, cocultivation of Ad.mda-7-infected P69 with DU-145 or BxPC-3 cells resulted in a statistically significant (Po0.03) decrease in invasion, whereas a similar assay incorporating infected P69 cells mixed with A549 (non-small-cell lung carcinoma (NSCLC)) cells did not alter invasion. Photomicrographs confirming this differential activity of secreted MDA-7/IL-24 protein are shown in Figure 3a and quantitation of these assays is shown in Figure 3b . These results indicate that secreted MDA-7/IL-24 can decrease tumor cell invasion in some, but not all, cancer cells, and that this effect is not simply a manifestation of decreased growth rate/survival of specific cancer cells. This 'antitumor (invasion inhibition) bystander effect' of secreted MDA-7/IL-24 protein can be projected to enhance the therapeutic properties of this cytokine and promote biologically relevant effects at a distance from its initial cellular site of synthesis and secretion.
Secreted MDA-7/IL-24 sensitizes specific cancer cells to radiation MDA-7/IL-24, administered by Ad.mda-7 or in specific instances by GST-MDA-7, enhances the sensitivity of human non-small-cell lung carcinoma (NSCLC), human breast carcinoma, and human and rodent malignant glioma cells to radiation Su et al., 2003a; Yacoub et al., 2003b Yacoub et al., , c, 2004 Sauane et al., 2004a) . In the case of A549 cells (NSCLC), in vivo tumor xenograft therapy studies employing Ad.mda-7 suggest that radiation inhibition of tumor growth is a consequence of indirect action of secreted MDA-7/IL-24 on tumor endothelial cells resulting in inhibition of tumor angiogenesis, rather than a direct sensitization effect on A549 cells (Nishikawa et al., 2004) . These studies prompted us to determine if secretion of MDA-7/IL-24 protein from normal cells could directly sensitize various tumor cells to the inhibitory action of ionizing radiation (IR). To address this possibility, P69 cells were seeded on plates and 24 h later they were infected with 100 pfu/cell of Ad.vec, Ad.mda-7 or Ad.mda-7 SP À , Figure 3 Cocultivation of Ad.mda-7-infected P69 cells with various tumor cells inhibits invasion. P69 cells were uninfected or infected with 100 pfu/cell of Ad.mda-7, and cocultivated with various tumor cells (DU-145, A549 and BxPC-3). After 48 h, cells (5 Â 10 4 ) were seeded in the upper compartment of the transwell unit and then incubated for 72 h at 371C. The lower compartment contained 0.5 ml of DMEM and 5% FBS. At the end of the invasion assay, the filters were removed, fixed and stained as indicated in Materials and methods. Invasion was determined by counting the cells that had migrated into the lower side of the filter with a microscope at Â 100. In all, 10 fields per cell line were counted. À , which results in secreted MDA-7/IL-24, inhibited agar growth, and this effect was enhanced when used in combination with 1 Gy of IR (Figure 4a ). With BxPC-3 cells, no significant effect on agar growth was observed following infection of P69 cells with any of the three viruses, whereas the addition of IR to cultures containing P69 cells infected with Ad.mda-7 significantly decreased BxPC-3 agar growth (Po0.01) (Figure 4b ). When A549 cells were assayed using the agar-diffusion method, no effect on agar growth following infection of normal P69 cells with any of the viruses was observed and simultaneous treatment with IR also had a minimal impact that did not correlate with secreted MDA-7/IL-24 (Figure 4c ). These studies document that secreted MDA-7/IL-24 can induce sensitivity to radiation in specific cancer cells. As observed for invasion inhibition, secreted MDA-7/IL-24 did not elicit this radiosensitization effect in A549 cells, whereas it did induce radiosensitization in DU-145 and BxPC-3 cells.
Secreted MDA-7/IL-24 sensitizes radiation-and mda-7/IL-24-resistant prostate cancer cells to the combinatorial action of these agents
Overexpression of bcl-x L or bcl-2 in diverse prostate cancer cells differentially protects them from apoptosis induction by Ad.mda-7 and promotes enhanced resistance to the toxic effects of IR ( Figure 5 ). To determine whether secreted MDA-7/IL-24 protein modifies this resistance, agar-diffusion studies were performed with PHFA cells in the base layer and various prostate cancer cells, either unmodified neomycin resistant (DUneo, PCneo and LNCneo) or modified to overexpress bcl-x L (DUxL cl46 or PCxL cl52) or bcl-2 (LNCb2 cl4) , in the agar overlay. Infection of normal PHFA cells with 100 pfu/ cell of Ad.mda-7, but not Ad.vec or Ad.mda-7-SP À , inhibited agar growth of all the three neomycin-resistant prostate tumor clones, with the greatest effect occurring in DUneo cells ( Figure 5) . Similarly, infection of PHFA with Ad.mda-7 promoted a small inhibition in agar growth of bcl-2-or bcl-x L -overexpressing clones of prostate tumor cells. When treated with 1 Gy of IR, agar growth of neomycin-resistant parental cells was inhibited to a greater degree than bcl-2-or bcl-x L -overexpressing cells. However, when PHFA cells were infected with Ad.mda-7, but not Ad.vec or Ad.mda-7 SP À , and parental and bcl-2-or bcl-x L -overexpressing clones were also treated with IR, a significant suppression in agar colony formation was noted, an effect that was qualitatively similar in both cell types ( Figure 5 ). These results suggest that a combination of IR plus secreted MDA-7/IL-24 can enhance sensitivity to radiation of inherently sensitive cancer cells, and it can also render normally radiation-resistant tumor cells responsive to IR.
In the case of NSCLC and rodent and human malignant glioma cells, a potential role of JNK signaling in mediating radiation enhancement of MDA-7/IL-24 Figure 4 Secreted MDA-7/IL-24 protein synergizes with IR in inhibiting anchorage-independent growth in specific cancer cells. P69 cells were seeded in 6-cm tissue culture plates and, 24 h later, were infected with 100 pfu/cell of Ad.vec, Ad.mda-7 or Ad.mda-7 SP À . At 6-8 h after infection, cells were washed extensively (5 Â with PBS) and then overlaid with 0.4% agar/medium containing 1 Â 10 5 target cells, DU-145 (a), BxPC-3 (b), or A549 (c). After 48 h, cells were either mock irradiated or irradiated with 1 Gy of g-ray. Cells were refed with 0.4% agar/medium every 3-4 days and colonies X2 mm were determined after 2-weeks growth. Results are the average of three plates7s.d. from the mean. *Po0.01 lethality has been documented Yacoub et al., 2003b) . To determine if the 'bystander radiation enhancement' effect of secreted MDA-7/IL-24 also proceeds through this signaling pathway, we tested the effect of SP600125, a specific JNK 1/2/3 inhibitor, on agar colony formation in an agar-diffusion assay ( Figure 5 ). Continuous incubation with 2 mM SP600125 did not block the ability of secreted MDA-7/IL-24 from Ad.mda-7-infected PHFA cells to inhibit agar growth of parental-neomycin-resistant or bcl-2-or bcl-x L -overexpressing prostate tumor cells. In contrast, SP600125 pretreatment before IR and continuous maintenance Figure 5 Secreted MDA-7/IL-24 protein synergizes with IR in inhibiting anchorage-independent growth in unmodified and bcl-2-family-overexpressing prostate tumor cells. PHFA cells were seeded in 6-cm tissue culture plates and, 24 h later, were infected with 100 pfu/cell of Ad.vec, Ad.mda-7 or Ad.mda-7-SP À . At 6-8 h after infection, cells were washed extensively (5 Â with PBS) and then overlaid with 0.4% agar/medium containing 1 Â 10 5 target cells, DUneo (a), DUxL (b), PCneo (c), PCxL (d), LNCneo (e), and LNCb2 (f). After 48 h, cells were either mock irradiated or irradiated with 1 Gy of g-ray. Cells were refed with 0.4% agar/medium every 3-4 days and colonies X2 mm were determined after 2 weeks growth. Results are the average of three plates7s.d. from the mean, *Po0.01. To determine the effect of JNK1/2/3 pathway, SP600125 (2 mM) was added to the initial agar medium and in the agar overlay feeding medium for the duration of the experiment MDA-7/IL-24 bystander antitumor activity Z Su et al in the agar overlay prevented the enhanced growth suppression of the secreted MDA-7/IL-24 plus IR in the various prostate tumor cells ( Figure 5 ). These results support the hypothesis that the radiosensitization effect of secreted MDA-7/IL-24 in combination with IR, in both sensitive and resistant prostate tumor cells, proceeds through JNK signaling, whereas the direct inhibitory activity of secreted MDA-7/IL-24 in suppressing agar growth of prostate tumor cells in the absence of IR is independent of JNK signaling.
Targeted expression of mda-7/IL-24 in human astrocytes using the excitatory amino acid 2 (EAAT2) promoter inhibits anchorage independence of established malignant glioma cells and radiosensitizes primary human malignant glioma cells
As documented previously, infection of both established and primary human malignant glioma cells with Ad.mda-7 or treatment with GST-MDA-7 suppresses growth and enhances their sensitivity to IR Yacoub et al., 2003b Yacoub et al., , c, 2004 . Experiments using the agar-diffusion approach were employed to determine if MDA-7/IL-24 secreted from PHFA-IM or PHFA also demonstrates antiproliferative and radiosensitization properties. We previously cloned and characterized the promoter gene region for the EAAT2 transporter and documented preferential expression in normal astrocytes Rothstein et al., 2005; Sitcheran et al., 2005) . A recombinant replicationincompetent adenovirus was generated, in which the EAAT2 promoter controls mda-7/IL-24 expression (Ad.EAAT2-mda-7). Infection of PHFA-IM cells with Ad.EAAT2-mda-7 or Ad.mda-7 (in which mda-7/IL-24 expression is controlled by the CMV promoter) results in the intracellular production and secretion of MDA-7/ IL-24 protein (Figure 6a ). The levels of intracellular and secreted MDA-7/IL-24 protein are greater using Ad.mda-7 than Ad.EAAT2-mda-7. To determine if this secreted MDA-7/IL-24 protein has biological activity, we employed the agar-diffusion overlay approach (Figure 6b ). PHFA-IM cells were infected with 100 pfu/cell of Ad.vec, Ad.EAAT2-mda-7 or Ad.mda-7, and 48 h later U87-MG cells were overlaid in 0.4% agar/ medium and colony formation after 3 weeks growth (with the addition of 0.4% agar/medium every 3-4 days) was determined (Figure 6b ). Both Ad.mda-7 and Ad.EAAT2-mda-7 reduced colony formation, with activity greater (as observed with MDA-7/IL-24 protein production and secretion) when delivered with a virus employing the CMV rather than the EAAT2 promoter. This result is interesting, but differs from that observed when PHFA-IM, P69 or FM516-SV cells were infected with Ad.mda-7 and DU-145 cells were seeded in the agar overlay, where different amounts of MDA-7/IL-24 protein were detected in the supernatant, whereas growth inhibition in agar was similar (Figure 1 ). It is possible that DU-145 cells respond to a lower threshold level of MDA-7/IL-24 protein, resulting in a plateau inhibition of anchorage-independent growth, whereas U87 MG cells display a classic dose-dependent inhibitory response to the secreted MDA-7/IL-24 protein.
A similar experiment was next performed using PHFA and primary human GBM cells (GBM6) (Yacoub et al., 2004) to recapitulate the environment that would be present in the context of a malignant glioma surrounded by normal astroctytes. vec, Ad.mda-7 or Ad.EAAT2-mda-7 were detected by Western blot analysis using rabbit anti-MDA-7/IL-24 antibody. For evaluation of loading controls, the same membrane was reprobed with mouse anti-EF-1a antibody. (b) Immortalized normal human fetal astrocytes (PHFA-IM) were seeded in 6-cm tissue culture plates. After 24 h, they were infected with 100 pfu/cell of Ad.vec, Ad.mda-7 or Ad.EAAT2.mda-7. At 6-8 h after infection, cells were washed extensively (5 Â with PBS) and then overlaid with 0.4% agar/medium containing 1 Â 10 5 target cells, U87-MG. Cells were refed with 0.4% agar/medium every 3-4 days and colonies X2 mm were determined after 2 weeks growth. Results are average of three plates7s.d. from the mean, *Po0.01. (c) PHFA cells were seeded in 6-cm tissue culture plates and, 24 h later, were infected with 100 pfu/cell of Ad.vec, Ad.mda-7, Ad.mda-7SP À or Ad.EAAT2-mda-7. At 6-8 h after infection, cells were washed extensively (5 Â with PBS) and then overlaid with 0.4% agar/medium containing 1 Â 10 5 target cells, GMB6. After 48 h, cells were either mock-irradiated or irradiated with 1 Gy of g-ray. Cells were refed with 0.4% agar/medium every 3-4 days and colonies X2 mm were determined after 2 weeks growth. Results are the average of three plates7s.d. from the mean. *Po0.01 MDA-7/IL-24 bystander antitumor activity Z Su et al PHFA cells were infected with Ad.vec, Ad.mda-7, Ad.EAAT2-mda-7 or Ad.mda-7-SP À (Sauane et al., 2004b) and overlaid with primary human GBM6 cells (Yacoub et al., 2004) . In this experiment, no significant inhibition of growth was evident in this population of primary GBM6 cells; however, when cells were also exposed to 1 Gy of IR, agar colony formation was significantly inhibited (Po0.01 for Ad.mda-7; Po0.03 for Ad.EAAT2-mda-7) in cells overlaying Ad.mda-7-and Ad.EAAT2-mda-7-infected PHFA cells, with the greatest response again observed under conditions of CMV regulating expression of mda-7/IL-24. A small inhibitory effect was observed as a result of IR treatment versus Ad.vec-or Ad.MDA-7-SP À -infected cultures, and no enhancement was observed with cocultivation conditions when PHFA cells were infected with Ad.MDA-7-SP À virus and treated with IR, supporting the role for secreted MDA-7/IL-24 in exerting this radiosensitization effect.
These studies are intriguing and support a potentially novel treatment paradigm using mda-7/IL-24. In the present experiments, the EAAT2 promoter was used to target MDA-7/IL-24 protein production and secretion from normal astrocytic cells, the major cellular component in the brain. This approach could in principle, however, be used with any normal target tissue in which a tissue-specific promoter is available to deliver and express mda-7/IL-24, for example, the tyrosinase promoter (melanocytes), albumin promoter (hepatocytes), probasin or prostate-specific antigen promoter (prostate epithelial cells). Transient delivery of mda-7/IL-24 could be by means of an adenovirus or any other type of delivery system, including other viruses or chemical delivery approaches, or long-term continuous expression could be achieved by genetically altering normal tissue (such as the liver), using lentiviruses or retroviruses, to stably produce and secrete the MDA-7/IL-24 protein. In addition, should insertion of the lentivirus or retrovirus, containing mda-7/IL-24, occur in a genomic locus in a normal cell that results in oncogene activation or transformation (through another mechanism, such as suppressor gene inactivation), the antitumor properties of mda-7/IL-24 would theoretically eliminate these evolving neoplastic cells. This innovative strategy would not only promote direct 'antitumor bystander' activity in a localized environment, but would also permit a novel means of producing MDA-7/IL-24 systemically, which could provide therapy for metastases, either singly or by subsequent treatment with IR, chemotherapy or immunotherapy.
Bystander activity is dependent on the presence of IL-20/IL-22 receptors on tumor cells
The resistance of specific tumor cells to the 'antitumor bystander' activity of MDA-7/IL-24 provoked the obvious question as to the mechanism underlying this differential response to this cytokine. To determine why specific cancer cells, such as DU-145 and BxPC-3, respond to secreted MDA-7/IL-24 by eliciting a decrease in anchorage independence, inhibition of invasion and radiosensitization, whereas other tumor cells, such as A549, do not respond with an 'antitumor bystander effect', experiments focused on the IL-20/IL-22 receptors that can bind MDA-7/IL-24 protein (Dumoutier et al., 2001; Wang et al., 2002; Pestka et al., 2004) . Using a sensitive reverse transcription (RT)-PCR reaction, we determined if the different cell types employed in our studies express IL-20R1, IL-20R2 and/or IL-22R1 receptor mRNAs (Figure 7) . These experiments confirmed the presence of a complete set of IL-20/IL-22 receptors in PHFA-IM, BxPC-3, FM516-SV, P69, DUneo, DUxL cl46, PCneo, PCxL cl52, LNCneo and LNCb2 cl4 cells. In contrast, a complete set of IL-20/ IL-22 receptor mRNAs was not present in A549 cells (Figure 7a ). This finding, relative to A549 not containing a full complement of IL-20/IL-22 receptors, is in agreement with a recent report by Chada et al. (2005) .
To verify that the receptor complexes, predicted by the presence of appropriate mRNAs, were functional and capable of responding to MDA-7/IL-24 protein secreted from Ad.mda-7-infected normal cells, we employed two different STAT3 activation assays (Dumoutier et al., 2001; Wang et al., 2002) . DU-145, A549 and BxPC-3 cells were treated for various times with conditioned medium from uninfected or Ad.mda-7-infected P69 cells and analysed for activation of the (Figure 8a ). These results were corroborated by an additional experimental approach measuring localization of STAT3 protein by immunofluorescence (Figure 8b ). STAT3 protein translocated into the nucleus after incubation for 1 or 4 h with conditioned medium from Ad.mda-7-infected PHFA-IM cells (containing secreted MDA-7/IL-24 protein) in DU-145 and BxPC-3 cells, but not in A549 cells (Figure 8b and data not shown).
As shown in Figure 7 , RNAs for the appropriate IL-20/IL-22 receptor complexes that mediate MDA-7/ IL-24 protein binding are present in the various prostate cancer cell lines (including bcl-2 and bcl-x L overexpressing clones), and the normal immortal cell lines (melanocyte, prostate epithelium and astrocyte) used in the present studies. These results argue that the ability of specific tumor cells to respond to secreted MDA-7/ IL-24 protein from normal cells resulting in a reduced ability of tumor cells to grow in an anchorageindependent manner, an inhibition of tumor cell invasion and an increase in sensitivity of cancer cells to radiation is a consequence of the presence of appropriate functional IL-20/IL-22 receptor complexes for MDA-7/IL-24 protein binding on tumor cells. Since IL-20/IL-22 receptors are present in the vast majority of normal and tumor cells, this limitation, that is, absence of a complete set of functional receptors for MDA-7/ IL-24, should not represent a major impediment limiting the clinical utility of this cytokine. Moreover, in the in vivo context, the ability of MDA-7/IL-24 to promote immune-modulating activity provides further confidence that this cytokine will retain significant antitumor therapeutic activity, even in the absence of a complete set of functional receptors on a minority of tumor cells.
Discussion
Experiments initially performed in the context of pancreatic carcinoma cells suggested that mda-7/IL-24 could promote potent 'bystander' antitumor activity (Gazdar and Minna, 2001; Su et al., 2001) . Although mda-7/IL-24 when administered by adenovirus has profound selective antitumor activity, pancreatic cancers display inherent resistance to this gene when Ad.mda-7 is administered at concentrations that effectively induce apoptosis in a broad-spectrum of other cancer cell types Lebedeva et al., 2005b) . This lack of activity is not a consequence of failure to express mda-7/IL-24 mRNA, but rather involves a translational suppression in conversion of this mRNA into protein Lebedeva et al., 2005b) . When infected with a high titer of Ad.mda-7 (200-300 pfu/cell), which significantly exceeds that required to induce apoptosis or infect >90% of the majority of other cancer cell types, both mda-7/IL-24 mRNA and protein are produced, resulting in apoptosis in specific pancreatic tumor cells with mutant K-ras (unpublished data). Similarly, infection of specific pancreatic cancer cells containing a K-ras mutation with high levels of a structurally different replication-incompetent adenovirus expressing mda-7/IL-24 also promotes apoptosis in these pancreatic tumor cells . In pancreatic carcinoma cells, a frequent and early occurrence in tumor development is mutation in the K-ras oncogene (B85-95%) (Hilgers and Kern, 1999; Hruban et al., 2001; Bardessy and DePinho, 2002) . Based on this consideration, experiments were performed to ascertain if inhibiting K-ras expression in pancreatic tumor cells could sensitize these cells to the apoptosis-inducing properties of Ad.mda-7. This indeed was the case, since specifically blocking K-ras expression using phosphorothioate oligonucleotides resulted in Figure 8 STAT3 activation in different cell lines. (a) Protein lysates were collected from untreated (DU-145, A549 and BxPC-3) cells and after treatment with medium lacking (À) or containing MDA-7/IL-24 following infection of PHFA-IM cells with 100 pfu/ cell of Ad.mda-7 for 10 min, 2 and 4 h. Samples (50 mg) were run on 8% SDS-PAGE, transferred to a nitrocellulose membrane and probed with rabbit anti-phospho-STAT3 and anti-STAT3 antibodies as described in 'Materials and methods'. pSTAT refers to phosphorylated STAT3 and tSTAT refers to total STAT3. (b) STAT3 protein localization was analysed by indirect immunofluorescence. DU-145 or A549 cells were fixed after treatment with MDA-7/IL-24 supernatant for different periods of time, and STAT3 protein was detected by indirect immunofluorescence using anti-phosphoSTAT3 antibody. Similar studies were performed with BxPC-3 cells (data not shown) production of MDA-7/IL-24 protein which correlated with rapid cell death, by apoptosis, in mutant K-rasexpressing pancreatic cancer cells .
A provocative observation was that transfection of pancreatic cancer cells with a K-ras antisense expression vector followed by infection with Ad.mda-7 in vitro resulted in a dramatic reduction in cloning ability in vitro and a complete loss of tumorigenic potential following injection of combination-treated cells into athymic nude mice. Since this combination treatment resulted in an estimated maximum of B8% of cells receiving both molecules, that is, B100% delivery of mda-7/IL-24 with Ad.mda-7, a maximum B3-4% transfection of cells with the K-ras antisense gene and potentiation of transfection following adenovirus infection (hence B8% transfection efficiency), whereas no tumors developed, we evoked the hypothesis that production and secretion of MDA-7/IL-24 protein (and/or potentially other gene products) by cells receiving both agents (presumptive 8% of the treated population) resulted in a potent 'bystander' antitumor effect in the adjacent tumor cells. Support for a direct biological effect of MDA-7/IL-24 protein in pancreatic cancer cells comes from the recent observation that treatment with purified GST-MDA-7 fusion protein induces apoptosis in normally resistant pancreatic tumor cells (Sauane et al., 2004b) . Similarly, decreased invasion and radiosensitization of BxPC-3 pancreatic tumor cells are observed in the presence of secreted MDA-7/IL-24 (Figures 3 and 4) . Additionally, administration of Ad.mda-7 (INGN 241) intratumorally in patients with advanced carcinomas and melanomas results in apoptosis in tumor cells receiving the mda-7/ IL-24 transgene, as well as death in tumor cells not initially receiving the virally-transduced gene, that is, B30% of the tumor mass is transduced with mda-7/IL-24 following a single Ad.mda-7 injection with B70% of the tumor cells showing detectable apoptosis Cunningham et al., 2005; Lebedeva et al., 2005a) . Whether this response reflects a direct effect of secreted MDA-7/IL-24 or an immune-mediated antitumor response, or a combination of both processes, remains to be determined.
The present study provides direct support for an antitumor, cancer-specific apoptosis induction and radiation sensitization 'antitumor bystander effect' of MDA-7/IL-24 following secretion from normal cells (promulgated by infection with Ad.mda-7). Unlike the ability of Ad.mda-7 and GST-MDA-7 to selectively kill cancer cells, which can occur in a receptor-independent manner and involves both a secretory and nonsecretory mode of action (Sauane et al., 2004a, b) , the ability of secreted MDA-7/IL-24 to suppress tumor cell growth, inhibit invasion and sensitize cancer cells to radiation is IL-20/IL-22 receptor dependent. The MDA-7/IL-24 signal-transduction pathway is activated through two different receptor complexes consisting of IL-20RA/ IL-20RB (IL-20R1/IL-20R2) and IL-22RA/IL20-RB (IL-22R1/IL-20R2). Ligand-mediated assembly of both receptor chains catalyses rapid activation of STAT3 and to a lesser extent, STAT1 (Parrish-Novack et al., 2002 ).
We presently demonstrate, using tumor cells that express (DU-145 and BxPC-3) or do not express detectable levels of IL-20/IL-22 receptors (A549), that the direct 'antitumor bystander' actions of secreted MDA-7/IL-24 are receptor-dependent. Infection of A549 cells, which lack a full complement of receptors for mda-7/IL-24, with Ad.mda-7 results in an inhibition of invasion at levels not reducing cell viability, suggesting that this effect may not be mediated by secreted MDA-7/IL-24, but rather is a consequence of intracellular MDA-7/IL-24 protein . In contrast, the ability of mda-7/IL-24 to inhibit angiogenesis appears to involve secretion of this cytokine and a direct effect on tumor vasculature . A recent study also suggests that the ability of radiation to enhance the antitumor activity of Ad.mda-7 in A549 NSCLC is a consequence of an indirect effect of secreted MDA-7/IL-24 on the tumor vasculature, by sensitizing vascular endothelial cells to radiation, rather than a direct effect of radiation on this specific tumor cell type (Nishikawa et al., 2004) . In the case of A549 cells, which lack a full complement of IL-20/IL-22 receptors ( Figure 7 ) and do not respond to secreted MDA-7/ IL-24 with respect to growth inhibition, suppressed invasion, radiosensitization or STAT3 activation (Figures 3, 4, 8) , functional receptors on tumor cells appear to be mandatory for the antitumor (suppression of anchorage-independent growth, apoptosis induction and invasion) and radiosensitization bystander effects. Moreover, previous studies confirm that MDA-7/IL-24 protein, but not IL-20 protein, kills human melanoma cells . However, both cytokines can bind to the IL-20 receptor and activate JAK/STAT signaling, suggesting that binding to the receptor by these two distinct cytokines, which are members of the IL-10 superfamily, can elicit different effects in the same target cell. The results presented herein provide several independent lines of evidence indicating that mda-7/ IL-24 elicits an 'antitumor bystander growth-inhibitory effect' in an IL-20/IL-22 receptor-dependent manner. This effect might occur by MDA7/IL-24-induced secretion of distinct cytokines that contribute to the observed 'antitumor bystander effects'. In addition to canonical IL20/IL-22 receptor complex formation (IL-22R1/IL-20R2 and IL-20R1/IL-20R2), the 'antitumor bystander effect' could also result from aberrant sharing of receptor chains (possibly IL-22R1/IL-20R1 or IL-20R2/IL-20R2) that would only occur at saturating cytokine levels. The increased affinity of MDA-7/IL-24, compared to IL-20, for the canonical receptor pairs may localize MDA-7/IL-24 to the cell surface for longer periods of time than IL-20. This may allow MDA-7/ IL-24 to engage other unknown cell surface molecules and signaling pathways that are only present in cancer cells, leading to the 'antitumor bystander effect'. Further studies are required to distinguish between these possible mechanisms of action of secreted MDA-7/ IL-24 in cancer cells.
Studies in human malignant glioma indicate that infection with Ad.mda-7 or treatment with GST-MDA-7 can sensitize these tumor cells to radiation both in vitro and in vivo Yacoub et al., 2003b Yacoub et al., , c, 2004 . In the case of primary human malignant glioma cells, MDA-7/IL-24 secreted by early-passage PHFA infected with Ad.mda-7 suppresses their anchorageindependent growth and enhances their response to radiation (Yacoub et al., 2004) . We now demonstrate that targeting mda-7/IL-24 expression in normal PHFA, using recombinant adenoviruses expressing mda-7/IL-24 under control of the CMV or EAAT2 promoter, results in enhanced sensitivity to radiation. Additionally, we show that secreted MDA-7/IL-24 can also suppress agar growth and enhance the radiosensitivity of prostate tumor cells. In human prostate tumor cells, overexpression of the antiapoptotic bcl-2 gene family members, bcl-2 or bcl-x L , differentially protects these cells from growth suppression and apoptosis induction by Ad.mda-7 . Although the precise mechanism remains to be defined, secreted MDA-7/ IL-24 also sensitizes these resistant prostate tumor cells to radiation through a process involving activation of JNK 1/2/3. These observations highlight an interesting aspect of the mda-7/IL-24 'antitumor bystander effect', an ability to enhance the sensitivity to IR of both mda-7/ IL-24-susceptible and -resistant tumor cell populations. Moreover, since this effect can occur even in the presence of small amounts of secreted MDA-7/IL-24 protein (barely detectable using polyclonal antibodies to MDA-7/IL-24 and Western blotting), secretion of this cytokine from normal cells should have a profound impact on tumor growth and radiosensitization in vivo, by directly affecting tumor cell survival and by inhibiting angiogenesis. Additionally, this intense antitumor effect should be evident in both inherently sensitive tumor cells and in tumor cells displaying resistance to either treatment regimen, mda-7/IL-24 or radiation, as single therapeutic approaches.
In summary, the present study sheds light on a notable aspect of mda-7/IL-24 of direct relevance to its profound antitumor activity in diverse cancers, namely its potent 'bystander' anticancer growth and survival inhibitory, anti-invasive and radiation sensitization properties. Secretion of MDA-7/IL-24 by normal cells when cocultivated with cancer cells directly kills tumor cells and also inhibits expression of the transformed state, as evidenced by a decreased ability of tumor cells to grow in an anchorage independent manner and an inhibition of tumor cell invasion. Additionally, secreted MDA-7/IL-24 promotes sensitivity to radiation in cancer cells, including tumor cells displaying innate resistance to this gene product because of overexpression of antiapoptotic proteins. These effects are dependent on the presence of IL-20/IL-22 receptor complexes for MDA-7/IL-24 on tumor cells. Based on the nearubiquitous activity of mda-7/IL-24 in cancer cells and its potent 'antitumor bystander' activity, this novel cytokine will, without doubt, have expanded therapeutic applications for the treatment of diverse primary and metastatic cancers Lebedeva et al., 2005a) . In this context, applications of purified MDA-7/ IL-24 protein may also prove amenable for cancer therapeutics (Sauane et al., 2004a) . Additionally, the present study highlights the significance of normal cells as contributors to the potent antitumor activity of MDA-7/IL-24, and they reveal a novel application of this cytokine to enhance its cancer therapeutic efficacy, that is, use of normal cells as a repository for producing low levels of MDA-7/IL-24 protein to facilitate both localized and systemic cancer therapies. If successful and nontoxic in vivo, constitutively expressing low levels of mda-7/IL-24 would permit a maximization of benefit of this novel anticancer gene therapy, potentially providing a means of preventing tumor and metastasis development at their inceptions.
Materials and methods
Cell cultures and culture conditions
Human DU-145, PC-3 and LNCaP prostate carcinoma cell lines and the human HeLa cervical carcinoma cell line were obtained from the ATCC and cultured in RPMI 1640 supplemented with 10% FBS, sodium pyruvate and nonessential amino acids. Human BxPC-3 pancreatic carcinoma cells, A549 human NSCLC and U87-MG malignant glioma cells were obtained from the ATCC and cultured in DMEM supplemented with 10% FBS. P69, an SV40-immortalized normal human prostate epithelial cell line, was provided by Dr Joy L Ware (Virginia Commonwealth University, Richmond, VA, USA) and grown under serum-free conditions as described previously (Bae et al., 1994) . GBM6 is a primary malignant glioma cell line maintained in athymic nude mice (Yacoub et al., 2004) . Neomycin-resistant DU-145 (DUneo), PC-3 (PCneo) and LNCaP (LNCneo) clones were generated as described . bcl-x L stable overexpressing DU-145 (DUxL cl46) and PC-3 (PCxL cl52) clones and a bcl-2 stable overexpressing LNCaP (LNCb2 cl4) clone were generated and cultured as described . GFP-expressing stable clones of HeLa cells were generated by cotransfection of HeLa cells with a pIRES-hrGFP-1a expression vector (Stratagene, La Jolla, CA, USA) and a hygromycin-resistant pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) using Lipofectamine (Invitrogen, Carlsbad, CA, USA). Clones were selected following growth in hygromycin, and resistant clones were isolated after approximately 2-3 weeks maintenance in RPMI 1640 containing 10% FBS and 200 mg/ ml hygromycin. GFP expression was confirmed using fluorescence microscopy and by both FACS and Western blot analyses. GFP-transformed cells were routinely maintained in RPMI supplemented with 10% FBS and 50 mg/ml hygromycin. FM516-SV, an SV40 immortalized human melanocyte cell line (Melber et al., 1989; Jiang et al., 1995) , and PHFA-IM, an hTERT immortalized human fetal astrocyte cell line , were grown in DMEM supplemented with 10% FBS. All cells were grown at 371C in a 5% CO 2 95% air humidified incubator. Early-passage PHFA were established in culture after isolation from second trimester (gestational age 16-19 weeks) human fetal brains obtained from elective abortions in full compliance with NIH guidelines as described previously . Cells were routinely monitored for mycoplasma infection and confirmed negative cultures were employed in the present study.
Adenovirus construction
The recombination replication-incompetent Ad.mda-7 was created in two steps as described previously and plaque purified by standard procedures (Su et al., 1997 (Su et al., , 1998 Holmes et al., 2003) . To produce Ad.EAAT2-mda-7, the EAAT2 promoter (À1979 to þ 43) was first cloned into the pCR1.2 (Invitrogen) vector and then subcloned into the p0TgCMV shuttle vector using the SacI/XbaI site from pCR2.1 to the same site of the p0TgCMV to replace the CMV promoter with the EAAT2 promoter . The complete open reading frame of mda-7/IL-24 was cloned into pCR2.1 and then subcloned into p0TgEAAT2 vector at the XbaI/HindIII site. Homologous recombination of the shuttle vector with E1-and E3-region-deleted parental adenoviral vector in Escherichia coli was used to produce the replicationincompetent Ad-expressing mda-7 under control of the EAAT2 promoter (Ad.EAAT2-mda-7) (Holmes et al., 2003; Su et al., 2005) . As a control, a replication-incompetent adenovirus lacking a gene insert (Ad.vec) was used (Su et al., 1998) . Cells were infected with various multiplicities of infection (m.o.i.) of (pfu)/cell of different Ads as indicated in the figure legends and as described previously .
RT-PCR of IL-20R1, IL-20R2 and IL-22R RNAs
Analysis of mda-7/IL-24 receptor expression, which consists of IL-20R1/IL-20R2 (Type 1 IL-20R) and IL-22R1/IL-20R2 (type 2 IL-20R) complexes, was determined as described previously . Total RNA was isolated from 10-cm dishes using guanidine isothiocyanate lysis, utilizing the RNAeasy Kit (Qiagen Inc., Valencia, CA, USA). RT was performed on 5 mg of total RNA with an oligo (dT) primer as described previously. cDNA corresponding to 5 ng of total RNA was amplified for 35 cycles by PCR with specific primers for IL-20R1, IL-20R2 and IL-22R1 as described (Blumberg et al., 2001) . The products were analysed on ethidium bromide-stained 1% agarose gels following electrophoresis.
Immunofluorescence DU-145, A549 and BxPC-3 cells were grown on chamber slides (Falcon-BD, CA, USA) fixed with 2% paraformaldehyde, permeabilized with 0.1% Triton X-100, and then incubated with primary antibody (anti-phospho STAT3). FITC-conjugated donkey anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) was used as secondary antibody for visualization on a Zeiss LSM 510 fluorescence microscope.
Western blotting assays
Cells were grown on 10-cm plates and protein extracts were prepared with RIPA buffer containing a cocktail of protease inhibitors. In all, 50 mg of protein was applied to 12% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with polyclonal or monoclonal antibodies to mda-7/IL-24 and EF-1a Su et al., 2003a) . mda-7/IL-24 agar-diffusion assays and mda-7/IL-24 agar-diffusion plus irradiation assays Normal cells, FM516-SV, P69, PHFA (passage 3-5) or PHFA-IM were seeded in 60 mm tissue culture plates at a density of 2 Â 10 5 , or 1Â 10 6 (PHFA). The next day, the cells were infected with various viruses, Ad.vec, Ad.mda-7, Ad.mda-7 SP À (an adenovirus containing mda-7/IL-24 devoid of its signal peptide and not secreted from cells) or Ad.EAAT2-mda-7, at various m.o.i.'s, as indicated in the figure legends; 6-8 h later, the cultures were washed 5 Â with PBS and then overlaid with 8 ml of complete growth medium containing 0.4% agar with 1 Â 10 5 indicator cells (DU-145, DUneo, DUxL, PCneo, PCxL, LNCneo, LNCb2, A549, BxPC-3, U87-MG or GBM6). In specific experiments, 48 h later the cultures were either unirradiated or irradiated at 1 Gy with IR using a CsCl 138 g-ray source. After 2-weeks incubation, with agar overlay growth medium added every 3-4 days, colonies X2 mm in size were enumerated. In experiments employing the JNK 1/2/3 inhibitor, SP600125, 2 mM of inhibitor was added to the initial agar medium and in the agar overlay feeding medium for the duration of the experiment (including replicate samples treated or untreated with IR). The data presented are the averages of three independent plates with s.d. Qualitatively similar results were obtained in two additional experiments.
Invasion assay
Invasive ability of DU-145, A549 and BxPC-3 cells incubated for 48 h with P69 cells uninfected or infected with 100 pfu/cell of Ad.mda-7 in vitro was determined as described previously . Invasion was measured by using 24-well BioCoat cell culture inserts with an 8-mm-porosity polyethyleneterepthylate membrane coated with Matrigel basement membrane matrix (100 mg/cm 2 ). Briefly, the Matrigel was allowed to rehydrate for 2 h at room temperature by adding warm, serum-free DMEM. The wells of the lower chamber were filled with DMEM containing 5% FBS. Cells (5 Â 10 4 ) were seeded in the upper compartment (6.25 mm membrane size) in serum-free DMEM. The invasion assay was performed at 371C in a 5% CO 2 humidified incubator for 72 h. At the end of the invasion assay, the filters were removed, fixed and stained with the RAL 555 staining kit. Cells on the upper surface of the filters were removed by wiping with a cotton swab, and invasion was determined by counting of the cells that had migrated to the lower side of the filter with a microscope at Â 100 magnification. Experiments were assayed in triplicate, and at least 10 fields were counted in each experiment.
Apoptosis (Annexin V binding) assay
Cells were trypsinized and washed with complete media and then twice with PBS. Aliquots of cells (5 Â 10 5 ) were resuspended in PBS (0.5 ml) and stained with APC-labeled Annexin-V (BD Biosciences, Palo Alto, CA, USA) according to the manufacturer's instructions. Propidium iodide (PI) was added to the samples after staining with Annexin-V to exclude late apoptotic and necrotic cells. The flow cytometry was performed immediately after staining.
Statistical analysis
Statistical analysis was performed using one-way analysis of variance (ANOVA), followed by Fisher's protected least significant difference analysis.
